Inhibition of dipeptidyl-peptidase IV does not increase circulating IGF-1 concentrations in growing pigs

Experimental Biology and Medicine

Volumn 231, Issue 8, 2006, Pages 1373-1378

  Faidley, T D ^a   Leiting, B ^a   Pryor, K D ^a   Lyons, K ^a   Hickey, G J ^a   Thompson, D R ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

DPP IV; Growth hormone releasing hormone; Sitagliptin analog

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GROWTH HORMONE RELEASING FACTOR; SITAGLIPTIN; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DRUG ACTIVITY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; GROWTH HORMONE BLOOD LEVEL; HORMONAL REGULATION; HORMONE DETERMINATION; MALE; NONHUMAN; PROTEIN EXPRESSION; SWINE;

ANIMALIA; SUS SCROFA; SUS SCROFA DOMESTICA;

EID: 33748300619     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1177/153537020623100811     Document Type: Article

References (31)

1. Hartman ML, Veldhuis JD, Thorner MO. Normal control of growth hormone secretion. Horm Res 40:37-47, 1993.
2. Frohman LA, Downs TR, Chomczynski P. Regulation of growth hormone secretion. Front Neuroendocrinol 13:344-405, 1992.
3. Froesch ER, Schmid C, Schwander J, Zapf J. Actions of insulin-like growth factors. Annu Rev Physiol 47:443-467, 1985.
4. Dubreuil P, Couture Y, Pelletier G, Petitclerc D, Delorme L, Lapierre H, Gaudreau P, Morisset J, Brazeau P. Effect of long-term administration of porcine growth hormone-releasing factor and(or) thyrotropin-releasing factor on growth hormone, prolactin and thyroxine concentrations in growing pigs. J Anim Sci 68:95-107, 1990.
5. Etherton TD, Wiggins JP, Chung CS, Evock CM, Rebhun JF, Walton PE. Stimulation of pig growth performance by porcine growth hormone and growth hormone-releasing factor. J Anim Sci 63:1389-1399, 1986.
6. Pommier SA, Dubreuil P, Pelletier G, Gaudreau P, Mowles TF, Brazeau P. Effect of a potent analog of human growth hormone-releasing factor on carcass composition and quality of crossbred market pigs. J Anim Sci 68:1291-1298, 1990.
7. Campbell RM, Bongers J, Felix AM. Rational design, synthesis, and biological evaluation of novel growth hormone releasing factor analogues. Biopolymers 37:67-88, 1995.
8. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214:829-835, 1993.
9. Drucker DJ. Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Expert Opin Investig Drugs 12:87-100, 2003.
10. Wiedeman PE, Trevillyan JM. Dipeptidyl peptidase IV inhibitors for the treatment of impaired glucose tolerance and type 2 diabetes. Curr Opin Investig Drugs 4:412-420, 2003.
11. Sorbera LA, Castaner J. MK-0431 - Agent for type 2 diabetes dipeptidyl-peptidase IV (CD26) inhibitor. Drugs Future 30:337-343, 2005.
12. Mentlein R, Schiemann F, Ludwig A, Brandt E. Modification of the biological activity of chemokines by dipeptidyl peptidase IV-a side effect in the use of inhibitors? Adv Exp Med Biol 524:37-47, 2003.
13. Frohman LA, Downs TR, Heimer EP, Felix AM. Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma. J Clin Invest 83:1533-1540, 1989.
14. Su CM, Jensen LR, Heimer EP, Felix AM, Pan YC, Mowles TF. In vitro stability of growth hormone releasing factor (GRF) analogs in porcine plasma. Horm Metab Res 23:15-21, 1991.
15. Bongers J, Lambros T, Ahmad M, Heimer EP. Kinetics of dipeptidyl peptidase IV proteolysis of growth hormone-releasing factor and analogs. Biochim Biophys Acta 1122:147-153, 1992.
16. Campbell RM, Stricker P, Miller R, Bongers J, Liu W, Lambros T, Ahmad M, Felix AM, Heimer EP. Enhanced stability and potency of novel growth hormone-releasing factor (GRF) analogues derived from rodent and human GRF sequences. Peptides 15:489-495, 1994.
17. Low LC. Growth hormone-releasing hormone: clinical studies and therapeutic aspects. Neuroendocrinology 53(Suppl 1):37-40, 1991.
18. Iovino M, Monteleone P, Steardo L. Repetitive growth hormone-releasing hormone administration restores the attenuated growth hormone (GH) response to GH-releasing hormone testing in normal aging. J Clin Endocrinol Metab 69:910-913, 1989.
19. Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 19:717-797, 1998.
20. Thompson JL, Butterfield GE, Marcus R, Hintz RL, Van Loan M, Ghiron L, Hoffman AR. The effects of recombinant human insulin-like growth factor-I and growth hormone on body composition in elderly women. J Clin Endocrinol Metab 80:1845-1852, 1995.
21. Kim D, Wang L, Beconi M, Eiermann GJ, Fisher MH, He H, Hickey GJ, Kowalchick JE, Leiting B, Lyons K, Marsilio F, McCann ME, Patel RA, Petrov A, Scapin G, Patel SB, Sinha Roy R, Wu JK, Wyvratt MJ, Zhang BB, Zhu L, Thornberry NA, Weber AE. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3- a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 48:141-151, 2005.
22. Boulanger L, Roughly P, Gaudreau P. Catabolism of rat growth hormone-releasing factor(1-29) amide in rat serum and liver. Peptides 13:681-689, 1992.
23. Boulanger L, Lazure C, Lefrancois L, Gaudreau P. Proteolytic degradation of rat growth hormone-releasing factor(1-29) amide in rat pituitary and hypothalamus. Brain Res 616:39-47, 1993.
24. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 85:9-24, 1999.
25. Weber AE. Dipeptidyl peptidase IV inhibitors for the treatment of diabetes. J Med Chem 47:4135-4141, 2004.
26. Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M, Snyder K, Hilliard D, Tanen M, Tanaka W, Wang AQ, Zeng W, Musson D, Winchell G, Davies MJ, Ramael S, Gottesdiener KM, Wagner JA. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 78:675-688, 2005.
27. Aleppo G, Moskal SF, 2nd, De Grandis PA, Kineman RD, Frohman LA. Homologous down-regulation of growth hormone-releasing hormone receptor messenger ribonucleic acid levels. Endocrinology 138:1058-1065, 1997.
28. Miki N, Ono M, Murata Y, Ohsaki E, Tamitsu K, Yamada M, Demura H. Regulation of pituitary growth hormone-releasing factor (GRF) receptor gene expression by GRF. Biochem Biophys Res Commun 224:586-590, 1996.
29. Nagakura T, Yasuda N, Yamazaki K, Ikuta H, Yoshikawa S, Asano O, Tanaka I. Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats. Biochem Biophys Res Commun 284:501-506, 2001.
30. Marguet D, Baggio L, Kobayashi T, Bernard AM, Pierres M, Nielsen PF, Ribel U, Watanabe T, Drucker DJ, Wagtmann N. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci U S A 97:6874-6879, 2000.
31. Tiruppathi C, Miyamoto Y, Ganapathy V, Leibach FH. Genetic evidence for role of DPP IV in intestinal hydrolysis and assimilation of prolyl peptides. Am J Physiol 265:G81-G89, 1993.